Toll-like receptor-4 (TLR4) agonist-based intranasal nanovaccine delivery system for inducing systemic and mucosal immunity

MA Bakkari, CK Valiveti, RS Kaushik… - Molecular …, 2021 - ACS Publications
Eliciting a robust immune response at mucosal sites is critical in preventing the entry of
mucosal pathogens such as influenza and severe acute respiratory syndrome coronavirus 2 …
被引用次数：31 相关文章

Toll-like Receptor-4 (TLR4) Agonist-Based Intranasal Nanovaccine Delivery System for Inducing Systemic and Mucosal Immunity

MA Bakkari, CK Valiveti, RS Kaushik… - Molecular …, 2021 - pubmed.ncbi.nlm.nih.gov
Eliciting a robust immune response at mucosal sites is critical in preventing the entry of
mucosal pathogens such as influenza and severe acute respiratory syndrome coronavirus 2 …

[引用][C] Toll-like Receptor-4 (TLR4) Agonist-Based Intranasal Nanovaccine Delivery System for Inducing Systemic and Mucosal Immunity

MA Bakkari, CK Valiveti, RS Kaushik… - Molecular …, 2021 - cir.nii.ac.jp
Toll-like Receptor-4 (TLR4) Agonist-Based Intranasal Nanovaccine Delivery System for
Inducing Systemic and Mucosal Immunity | CiNii Research CiNii 国立情報学研究所 学術情報 …

Toll-like Receptor-4 (TLR4) Agonist-Based Intranasal Nanovaccine Delivery System for Inducing Systemic and Mucosal Immunity.

MA Bakkari, CK Valiveti, RS Kaushik… - Molecular …, 2021 - europepmc.org
Eliciting a robust immune response at mucosal sites is critical in preventing the entry of
mucosal pathogens such as influenza and severe acute respiratory syndrome coronavirus 2 …